Details

Autor(en) / Beteiligte

• Song, Ke
• Yang, Xinyan
• An, Geng
• Xia, Xinyu
• Zhao, Jiexiang
• Xu, Xiaoheng
• Wan, Cong
• Liu, Tianyuan
• Zheng, Yi
• Ren, Shaofang
• Wang, Mei
• Chang, Gang
• Cronin, Shane J. F.
• Penninger, Josef M.
• Jing, Tao
• Ou, Xianghong
• Rao, Shuan
• Liu, Zhaoting
• Zhao, Xiao-Yang

Titel

Targeting APLN/APJ restores blood-testis barrier and improves spermatogenesis in murine and human diabetic models

Ist Teil von

• Nature communications, 2022-11, Vol.13 (1), p.7335-7335, Article 7335

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Type 2 diabetes mellitus is one of the most prevalent metabolic diseases presenting with systemic pathologies, including reproductive disorders in male diabetic patients. However, the molecular mechanisms that contributing to spermatogenesis dysfunction in diabetic patients have not yet been fully elucidated. Here, we perform STRT-seq to examine the transcriptome of diabetic patients’ testes at single-cell resolution including all major cell types of the testis. Intriguingly, whereas spermatogenesis appears largely preserved, the gene expression profiles of Sertoli cells and the blood-testis barrier (BTB) structure are dramatically impaired. Among these deregulate pathways, the Apelin (APLN) peptide/Apelin-receptor (APJ) axis is hyper-activated in diabetic patients’ testes. Mechanistically, APLN is produced locally by Sertoli cells upon high glucose treatment, which subsequently suppress the production of carnitine and repress the expression of cell adhesion genes in Sertoli cells. Together, these effects culminate in BTB structural dysfunction. Finally, using the small molecule APLN receptor antagonist, ML221, we show that blocking APLN/APJ significantly ameliorate the BTB damage and, importantly, improve functional spermatogenesis in diabetic db/db mice. We also translate and validate these findings in cultured human testes. Our findings identify the APLN/APJ axis as a promising therapeutic target to improve reproduction capacity in male diabetic patients. Type 2 diabetes often presents with reproductive disorders, including reduced male and female fertility. Here they show that diabetes disrupts the APLN signaling axis in the testes and that spermatogenesis can be restored through treatment with an APLN antagonist.